title: In vitro combination of voriconazole and miltefosine against clinically relevant molds.
abstract: Invasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus. Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Imbert
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Palous
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Meyer
authors.affiliation: Université Paris-Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Dannaoui
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France Sorbonne Universités, UPMC Univ Paris 06, CIMI-Paris, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Mazier
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France Sorbonne Universités, UPMC Univ Paris 06, CIMI-Paris, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Datry
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France Sorbonne Universités, UPMC Univ Paris 06, CIMI-Paris, Paris, France arnaud.fekkar@psl.aphp.fr.
authors.forename: A
authors.initials: A
authors.lastname: Fekkar
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001230:Aspergillus / Q000187:drug effects* / Q000302:isolation & purification; D002175:Candida / Q000187:drug effects; D025141:Drug Resistance, Fungal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D060585:Fusariosis / Q000188:drug therapy / Q000382:microbiology; D005670:Fusarium / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000494:pharmacology; D021681:Scedosporium / Q000187:drug effects; D065819:Voriconazole / Q000494:pharmacology*
chemical_list: D000935:Antifungal Agents; D010767:Phosphorylcholine; C039128:miltefosine; D065819:Voriconazole